The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Official Title: A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Study ID: NCT01461538
Brief Summary: This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.
Detailed Description:
Minimum Age: 6 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Alabama at Birmingham, Birmingham, Alabama, United States
City of Hope, Duarte, California, United States
PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists, Oxnard, California, United States
Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
Ocala Oncology Center, Ocala, Florida, United States
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States
New York Oncology Hematology, P.C., Albany, New York, United States
University Hospitals Case Medical Center, Cleveland, Ohio, United States
Willamette Valley Cancer and Research / USOR, Eugene, Oregon, United States
Northwest Cancer Specialists, P.C., Tulatin, Oregon, United States
St. Francis Hospital, Greenville, South Carolina, United States
Texas Oncology - Bedford, Bedford, Texas, United States
Texas Oncology - Medical City Dallas, Dallas, Texas, United States
Texas Oncology - Dallas Presbyterian, Dallas, Texas, United States
Texas Oncology Denton South, Denton, Texas, United States
Texas Oncology - Fort Worth 12th Avenue, Fort Worth, Texas, United States
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
MD Anderson Cancer Center Leukemia Group, Houston, Texas, United States
Texas Oncology - Central Austin Cancer Center, Round Rock, Texas, United States
Cancer Centers of South Texas - HOAST, San Antonio, Texas, United States
Texas Oncology - Waco, Waco, Texas, United States
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
Puget Sound Cancer Centers, Edmonds, Washington, United States
Cancer Care Northwest, Spokane Valley, Washington, United States
Yakima Valley Memorial Hospital / North Star Lodge, Yakima, Washington, United States
Name: Neil Josephson, MD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR